Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Cases · November 19, 2018

Locally Advanced Hormone Receptor Positive Breast Cancer With Multiple Axillary LN Involvement

Written by
Sameer Nasir MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • heba  abusin

    Nov 19, 2018

    Before decision regarding SLND, what is the metastatic work up and KI67, chronic diseases and PS ?

  • N Cul

    Nov 23, 2018

    Not necessary,as cancer may be in lungs or viseral. CT or MRI more useful.

  • surapong  supaporn

    Nov 23, 2018

    Adjuvant aromatase inhibitor if luminalA..tamoxifen is contraindicated 
    21 recurrent score might be beneficial for decision making about chemo therapy 
    69 years old may not need alnd but radiation therapy to whole breast and regional nodes
    Alnd is still an option 

  • DANIEL CAMPOS

    Nov 23, 2018

    I would start hormone treatment with aromatase inhibitor identifying a measurable lesion to evaluate response. After 90 days of medication and attending especially the evolution of his thromboembolic disease, I would think about the locoregional actinic treatment if I have response. I do not see any usefulness of the ALND.

  • [email protected] [email protected]

    Nov 24, 2018

    Was it enough to have targeted axillary lymph node dissection only?

  • Jayaprakash Madhavan

    Nov 24, 2018

    She has ER +ve HER2 _ve T2 N1 disease.Being a luminal A type  ALD  may be avoided. She needs adj AI.she may be candidate for adjuvant radiation as 3 LN are 
    + VE  ONE with ene

  • JOSE FERNANDO ROBLEDO

    Nov 25, 2018

    Given that a metastatic lymph node was proven positive upfront she would not qualify por Z0011 or Amaros trials. I think she had an indication por lumpectomy + lymph node dissection or to enrole in  a neoadjuvant primary systemic therapy  trial like the Alliance

  • Samaneh Sarbaz

    Nov 29, 2018

    First of all,PS,metastatic work up and ki67 are  necessary

  • Apr 20, 2024

    Pending Moderator approval.
    Delete

Further Reading